CZP treatment was associated with higher Week 12 ACR20 responses versus placebo ( with non-MTX disease modifying antirheumatic drugs [ DMARDs ] , 74.2 % vs. 20.0 % ; without [ monotherapy ] , 59.3 % vs. 8.2 % ) and inhibition of radiographic progression at Week 24 ( mTSS CFB ; with non-MTX DMARDs , 0.24 vs. 1.61 ; monotherapy , 0.68 vs. 3.65 ) .